We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
BeyondSpring Inc | NASDAQ:BYSI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.065 | -2.56% | 2.475 | 2.44 | 2.53 | 2.5999 | 2.4101 | 2.49 | 15,385 | 20:26:45 |
The poster, titled, “Immune Activation with Plinabulin Enhances Anti-tumor Response Combining Radiation with Immune Checkpoint Blockade,” will be presented by Dr. Steven H. Lin, MD., Ph.D., physician-scientist, radiation oncologist and professor who specializes in thoracic malignancies at The University of Texas MD Anderson Cancer Center.
Additional presentation details are as follows:
About BeyondSpringBeyondSpring (NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company is advancing its first-in-class lead asset, Plinabulin, as a direct anti-cancer agent in various cancer indications and to prevent chemotherapy-induced neutropenia. Its pipeline also includes three preclinical immuno-oncology assets. Additionally, BeyondSpring’s subsidiary, SEED Therapeutics, leverages a proprietary targeted protein degradation (TPD) drug discovery platform and has an initial R&D collaboration with Eli Lilly. Learn more by visiting https://beyondspringpharma.com, and follow us on LinkedIn and Twitter.
Investor Contact:IR@beyondspringpharma.com
Media Contact:PR@beyondspringpharma.com
1 Year BeyondSpring Chart |
1 Month BeyondSpring Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions